Clariane SE (CHIX:CLARIP) YoY EBITDA Growth: 5.26% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:CLARIP Clariane SE CHIX:CLARIP
61 GF Score
Price €4.06
GF Value €2.45
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Clariane SE YoY EBITDA Growth?

Clariane SE CHIX:CLARIP 61 YoY EBITDA Growth is 5.26% as of Jun. 2026. GuruFocus rates CHIX:CLARIP with a GF Score™ of 61/100 and a GF Value™ of €2.45 (Significantly Overvalued). The stock has 8 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Clariane SE's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 5.26%.

Clariane SE's EBITDA per Share for the six months ended in Jun. 2026 was €1.36.

Clariane SE YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Clariane SE's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clariane SE YoY EBITDA Growth Chart

Clariane SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 -1.86 18.62 -17.95 -29.42

Clariane SE Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 410.96 -43.29 -71.41 22.79 5.26
CHIX:CLARIP
61GF Score
Clariane SE CHIX:CLARIP
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clariane SE YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Clariane SE's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(3.232-4.579)/ | 4.579 |
=-29.42 %

Clariane SE's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(1.361-1.293)/ | 1.293 |
=5.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 5.26% mean?
Clariane SE (CHIX:CLARIP) has a YoY EBITDA Growth of 5.26% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Clariane SE and its competitors.
Is Clariane SE's YoY EBITDA Growth too high?
Clariane SE's current YoY EBITDA Growth is 5.26%. Overall, Clariane SE has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's YoY EBITDA Growth compare to HCA and THC?
Clariane SE's YoY EBITDA Growth of 5.26% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Clariane SE and its competitors. Clariane SE's current YoY EBITDA Growth is 5.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (CHIX:CLARIP) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.45, compared to a current price of €4.06 — trading 65.7% above its estimated fair value. The current YoY EBITDA Growth is 5.26%. Clariane SE's overall GF Score™ is 61/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Clariane SE (CHIX:CLARIP), the current YoY EBITDA Growth is 5.26% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clariane SE (CHIX:CLARIP) Overvalued in 2026?

Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued. The current stock price of €4.06 is trading 65.7% above its estimated GF Value™ of €2.45. GuruFocus considers Clariane SE to be Significantly Overvalued.

Key valuation signals for CHIX:CLARIP:

  • YoY EBITDA Growth: 5.26%
  • GF Value™: €2.45 vs. price of €4.06 (65.7% above fair value)
  • GF Score™: 61/100 with 8 warning signs

No single metric tells the full story. See the CHIX:CLARIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clariane SE Business Description

Address 21-25, Rue Balzac, Paris, FRA, 75008
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
61GF Score

Get the complete analysis for CHIX:CLARIP

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.06
Price
€2.45
GF Value